Myocardial Minimal Damage After Rapid Ventricular Pacing

Not Applicable

Completed

• Conditions: Antitachycardia Pacing

• Registration Number: NCT02362802
• Lead Sponsor: Deutsches Herzzentrum Muenchen

Brief Summary

This study aims to investigate the impact of antitachycardia pacing ( ATP) on the myocardial tissue with respect to its potential micro damage measured by several myocardial markers, especially by high-sensitive TroponinT.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2015-02-01
• Study First Submitted QC: 2015-02-12
• Study First Posted: 2015-02-13
• Primary Completion: 2017-05-31
• Study Completion: 2018-01-31
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-17
• Last Update Posted: 2023-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 149

Inclusion Criteria

• All patients for de-novo implantation of a transvenous ICD (single chamber, dual chamber or cardiac resynchronization tehrapy) with left pectoral device position and planned apical location of the right ventricular defibrillation electrode.

Exclusion Criteria

• Resuscitation, cardiac surgical procedure, acute coronary syndrome, acute myocardial infarction, coronary revascularisation, cardioversion or ablation during the past 4 weeks, if baseline high-sensitive Troponin T is elevated
• Known stenosis of coronary vessels with indication for coronary intervention or operative revascularisation
• Intracardiac thrombus or general contraindication against ventricular burst stimulation or intraoperative ICD-testing
• Atypical lead implantation with indication for defibrillation threshold testing by induction of ventricular fibrillation
• Right sided implantation of ICD
• Planned electrical cardioversion
• Lead explantation or -extraction during procedure
• Redo procedure (except of additional implantation of a right ventricular ICD lead)
• Present temporary pacemaker electrode
• ASA >= IV or NYHA IV
• Cardiogenic shock
• Pulmonary embolism, cerebrovascular insult or dialysis in the past 4 weeks
• Lack of consent of patient
• Minority of patient

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
High sensitive Troponin	14-20 hours

Trial Locations

Locations (1)

Deutsches Herzzentrum Muenchen; 🇩🇪 Munich, Germany